Factors associated with mortality in hospitalised, non-severe, older COVID-19 patients - the role of sarcopenia and frailty assessment.
COVID-19
Dynapenia
Frailty
Handgrip strength
Rockwood
SARC-F
Sarcopenia
Skeletal muscles
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
07 12 2022
07 12 2022
Historique:
received:
17
05
2022
accepted:
31
10
2022
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
COVID-19 has affected older persons the most. The propensity to have severe COVID-19 or die of the infection was especially prevalent among older subjects with multimorbidity, frailty and sarcopenia. The aim of our study was to check which of the simple clinical biomarkers, including the assessment of muscle and frailty, would associate with the survival and the length of hospital stay in older patients with COVID-19. An additional aim was to report the influence of chronic diseases, chronic medication use, and COVID-19 signs and symptoms on the aforementioned outcome measures. The CRACoV study was a prospective single-center (University Hospital in Krakow, Krakow, Poland) observational study of clinical outcomes in symptomatic COVID-19 patients that required hospital treatment. We analysed data of persons aged ≥ 65 years. We assessed muscular parameters in accordance with EWGSOP2, frailty with the Rockwood Clinical Frailty Scale. We used the data of the initial and 3-month assessment. Demographic characteristics, past medical history, and baseline laboratory values were gathered as a part of routine care. We calculated sex and age, and additionally number-of-diseases adjusted odds ratios of mortality associated with studied factors and betas of the relation with these factors and the length of hospital stay. The mean (standard deviation, SD) age of 163 participants (44.8% women, 14.8% died) was 71.8 (5.6) years, age range 65-89 years. One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death, and 16.8 h longer hospital stay (p = 0.01). One score greater Rockwood was associated with 86% (p = 0.002) greater risk of death, but was unrelated to the length of hospital stay. Hand grip strength and dynapenia were unrelated to mortality, but dynapenia was related to longer hospital stay. Probable sarcopenia was associated with 441% (p = 0.01) greater risk of death. In conclusion, the patient assessment with SARC-F and the Rockwood Clinical Frailty Scale may significantly improve the prediction of outcomes in older patients with COVID-19 and by extension might be of use in other acute severe infections. This, however, requires further research to confirm.
Sections du résumé
BACKGROUND
COVID-19 has affected older persons the most. The propensity to have severe COVID-19 or die of the infection was especially prevalent among older subjects with multimorbidity, frailty and sarcopenia. The aim of our study was to check which of the simple clinical biomarkers, including the assessment of muscle and frailty, would associate with the survival and the length of hospital stay in older patients with COVID-19. An additional aim was to report the influence of chronic diseases, chronic medication use, and COVID-19 signs and symptoms on the aforementioned outcome measures.
METHODS
The CRACoV study was a prospective single-center (University Hospital in Krakow, Krakow, Poland) observational study of clinical outcomes in symptomatic COVID-19 patients that required hospital treatment. We analysed data of persons aged ≥ 65 years. We assessed muscular parameters in accordance with EWGSOP2, frailty with the Rockwood Clinical Frailty Scale. We used the data of the initial and 3-month assessment. Demographic characteristics, past medical history, and baseline laboratory values were gathered as a part of routine care. We calculated sex and age, and additionally number-of-diseases adjusted odds ratios of mortality associated with studied factors and betas of the relation with these factors and the length of hospital stay.
RESULTS
The mean (standard deviation, SD) age of 163 participants (44.8% women, 14.8% died) was 71.8 (5.6) years, age range 65-89 years. One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death, and 16.8 h longer hospital stay (p = 0.01). One score greater Rockwood was associated with 86% (p = 0.002) greater risk of death, but was unrelated to the length of hospital stay. Hand grip strength and dynapenia were unrelated to mortality, but dynapenia was related to longer hospital stay. Probable sarcopenia was associated with 441% (p = 0.01) greater risk of death.
CONCLUSIONS
In conclusion, the patient assessment with SARC-F and the Rockwood Clinical Frailty Scale may significantly improve the prediction of outcomes in older patients with COVID-19 and by extension might be of use in other acute severe infections. This, however, requires further research to confirm.
Identifiants
pubmed: 36476473
doi: 10.1186/s12877-022-03571-w
pii: 10.1186/s12877-022-03571-w
pmc: PMC9727948
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
941Subventions
Organisme : Narodowe Centrum Badań i Rozwoju
ID : SZPITALE-JEDNOIMIENNE/18/2020
Informations de copyright
© 2022. The Author(s).
Références
J Hypertens. 2022 Apr 1;40(4):666-674
pubmed: 34889863
Mol Psychiatry. 2021 Sep;26(9):5199-5212
pubmed: 33536545
Clin Nutr. 2022 Dec;41(12):2910-2917
pubmed: 35282986
Swiss Med Wkly. 2021 Jul 19;151:w20572
pubmed: 34324697
Ann Intensive Care. 2022 Feb 20;12(1):17
pubmed: 35184215
ERJ Open Res. 2022 Apr 11;8(2):
pubmed: 35415186
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e110-e116
pubmed: 33780535
Clin Nutr. 2022 Dec;41(12):2965-2972
pubmed: 34465493
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e38-e45
pubmed: 33216846
BMC Med. 2020 Nov 10;18(1):355
pubmed: 33167965
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36
pubmed: 27066316
Nutrients. 2022 Feb 21;14(4):
pubmed: 35215562
JAMA Netw Open. 2021 Nov 1;4(11):e2133090
pubmed: 34779847
Front Aging Neurosci. 2014 Jul 28;6:192
pubmed: 25120482
Folia Med Cracov. 2021 Dec 28;61(4):5-44
pubmed: 35180200
Aging Clin Exp Res. 2021 Jul;33(7):1821-1829
pubmed: 33506313
Am J Cardiol. 2021 Mar 1;142:158-159
pubmed: 33417877
Kurume Med J. 2021 Dec 15;66(4):195-201
pubmed: 34690206
J Am Geriatr Soc. 2021 Oct;69(10):2722-2731
pubmed: 34124775
Clin Nutr. 2022 Dec;41(12):2934-2939
pubmed: 34893357
BMJ Open. 2021 Jul 22;11(7):e051237
pubmed: 34301668
Intern Emerg Med. 2021 Jun;16(4):1005-1015
pubmed: 33893976
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Clinics (Sao Paulo). 2021 Dec 06;76:e3369
pubmed: 34878031
Front Med (Lausanne). 2021 Nov 18;8:767110
pubmed: 34869479
J Am Geriatr Soc. 2021 Sep;69(9):2419-2429
pubmed: 34048599
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):159-168
pubmed: 35018725
Clin Nutr ESPEN. 2022 Apr;48:158-166
pubmed: 35331486
Aging Clin Exp Res. 2020 Sep;32(9):1897-1905
pubmed: 32705587
Nutrition. 2021 Nov-Dec;91-92:111417
pubmed: 34399402
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1136-1143
pubmed: 34363345
J Am Med Dir Assoc. 2022 Mar;23(3):414-420.e1
pubmed: 34990587
Int J Infect Dis. 2022 May;118:89-94
pubmed: 35172182
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
Adv Exp Med Biol. 2020;1216:39-50
pubmed: 31894545
Lancet Reg Health Am. 2022 Apr;8:100177
pubmed: 35018359
Pharmaceuticals (Basel). 2022 Jan 08;15(1):
pubmed: 35056135
BMC Geriatr. 2022 Feb 17;22(1):132
pubmed: 35172759
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
BMC Med. 2021 Feb 22;19(1):51
pubmed: 33612113
Aging Dis. 2020 Dec 1;11(6):1345-1351
pubmed: 33269092
Int J Environ Res Public Health. 2021 Jul 29;18(15):
pubmed: 34360301
BMC Geriatr. 2019 Jul 5;19(1):186
pubmed: 31277579
Adv Exp Med Biol. 2021;1353:91-113
pubmed: 35137370
PLoS One. 2021 Feb 11;16(2):e0246825
pubmed: 33571280
Aging Clin Exp Res. 2021 Oct;33(10):2887-2898
pubmed: 34328636
J Affect Disord. 2022 Jun 15;307:108-114
pubmed: 35339571
Aging Clin Exp Res. 2022 Jan;34(1):249-256
pubmed: 34716570
PLoS One. 2021 Dec 9;16(12):e0261061
pubmed: 34882740
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1871-1878
pubmed: 34523262
Ann Nutr Metab. 2021;77(6):324-329
pubmed: 34673644